Core Viewpoint - The company, Zhongyuan Xiehe (600645), is committed to advancing stem cell drug research and development, enhancing its R&D system, and deepening collaborations with top-tier hospitals and research institutions to establish a robust R&D technology platform [1] Group 1: R&D Strategy - The company will continue to enrich and expand its R&D pipeline, accelerating the transformation and market promotion of new products [1] - The focus will be on both domestic market development and proactive international market positioning [1] Group 2: Collaboration and Partnerships - The company aims to promote the development of cell therapy business through diversified collaboration models [1]

Group 1 - The Shandong Yantai Development and Reform Commission announced the inclusion of "Stem Cell New Drug Research and Transformation Application Engineering Research Center" by Shandong Baihong Stem Cell Biotechnology Co., Ltd. in the list of newly recognized engineering research centers for 2025 [1] - The successful inclusion reflects the increasing research and transformation capabilities in the biomedicine sector within the Muping District, which is significant for promoting technological advancement and enhancing core competitiveness [1] - The district's Development and Reform Bureau will continue to strengthen the cultivation and supervision of various innovation platforms, further promoting the transformation of scientific achievements into new productive forces [1]

Core Viewpoint - The article highlights the challenges faced by biopharmaceutical companies in Shenzhen regarding the approval of production licenses for standalone factory buildings, emphasizing the need for clearer regulations to support the industry's growth [1][2][3]. Group 1: Industry Challenges - Biopharmaceutical companies are struggling to find suitable standalone factory buildings of approximately 7,000 square meters for the commercialization of new stem cell drugs [1]. - The "industrial building up" policy in Shenzhen has not significantly benefited pharmaceutical companies, as they require standalone buildings to obtain production licenses [1]. - Many companies face a dilemma between choosing standalone buildings, which are more likely to receive production licenses but are often too large for their needs, and opting for "industrial building up," which carries the risk of not obtaining the necessary licenses [1]. Group 2: Regulatory Environment - The Guangdong Provincial Drug Administration has introduced a "one enterprise, one policy" approach to improve service for companies, but many firms find the limited successful cases of "industrial building up" to be of little reference value [2]. - The lack of clear and transparent rules creates uncertainty for biopharmaceutical companies, which are particularly vulnerable during their early stages of development [2]. - There is a call for the establishment of explicit rules for biopharmaceutical companies to alleviate the anxiety surrounding the approval process and to foster a more predictable regulatory environment [3].